We are here!3 May 2026 10:21
A simple bridge: $100m asset – $46m Canmax – ~$15m further capex – execution discount (say 50%) = ~$20m residual equity value, before further dilution. That’s ~£15m vs £3.5m today, suggesting the market is pricing additional impairment scenarios (enforcement by Canmax, plant failure, deeper dilution).
Catalysts to watch :
1. May–June 2026: Xinhai plant commissioning results — the binary event
2. Production data: continuous run-time, recoveries, concentrate grade
3. 30 June 2026: Long Stop Date — extension, new buyer, or enforcement
4. Any further placing terms (size, discount, participants)
5. Canmax conversions (each tells you about Canmax’s stance — supportive vs settling)
6. Spodumene price trajectory
Bull / bear in one line each
• Bull: Plant commissions, Zulu produces stable concentrate, Canmax refinanced or replaced, equity captures meaningful share of a $100m asset on a £3.5m base
• Bear: Commissioning slips again, 30 June passes without resolution, Canmax enforces or imposes further punitive terms, equity is diluted to a stub or wiped
Bottom line:
PREM is a binary, time-boxed equity option on Zulu commissioning succeeding in Q2 2026 and the Canmax situation being resolved without enforcement. The asymmetry exists — at this market cap there’s a credible multi-bagger path — but the base rate on AIM resource stories failing at exactly this stage (post-commissioning issues, secured creditor pressure, perpetual dilution) is high. The next ~60 days will make or break.